0001209191-22-032783.txt : 20220531 0001209191-22-032783.hdr.sgml : 20220531 20220531144453 ACCESSION NUMBER: 0001209191-22-032783 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220527 FILED AS OF DATE: 20220531 DATE AS OF CHANGE: 20220531 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LILLY ENDOWMENT INC CENTRAL INDEX KEY: 0000316011 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-06351 FILM NUMBER: 22982654 BUSINESS ADDRESS: STREET 1: 2801 NORTH MERIDIAN STREET CITY: INDIANANAPOLIS STATE: IN ZIP: 46208 BUSINESS PHONE: 3179245471 MAIL ADDRESS: STREET 1: 2801 NORTH MERIDIAN ST CITY: INDIANAPOLIS STATE: IN ZIP: 46208 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ELI LILLY & Co CENTRAL INDEX KEY: 0000059478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 350470950 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: LILLY CORPORATE CTR STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 BUSINESS PHONE: 3172762000 MAIL ADDRESS: STREET 1: LILLY CORPORATE CENTER STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 FORMER COMPANY: FORMER CONFORMED NAME: LILLY ELI & CO DATE OF NAME CHANGE: 19941024 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-05-27 0 0000059478 ELI LILLY & Co LLY 0000316011 LILLY ENDOWMENT INC 2801 NORTH MERIDIAN STREET INDIANAPOLIS IN 46208-0068 0 0 1 0 Common Stock 2022-05-27 4 S 0 4100 314.44 D 105029710 D Common Stock 2022-05-27 4 S 0 13605 315.279 D 105016105 D Common Stock 2022-05-27 4 S 0 12324 316.441 D 105003781 D Common Stock 2022-05-27 4 S 0 36194 317.156 D 104967587 D Common Stock 2022-05-27 4 S 0 26801 318.555 D 104940786 D Common Stock 2022-05-27 4 S 0 44629 319.378 D 104896157 D Common Stock 2022-05-27 4 S 0 25542 320.114 D 104870615 D Common Stock 2022-05-27 4 S 0 11262 321.27 D 104859353 D Common Stock 2022-05-27 4 S 0 8400 322.513 D 104850953 D Common Stock 2022-05-27 4 S 0 17143 323.421 D 104833810 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $313.84 to $314.83, inclusive. The reporting person undertakes to provide to Eli Lilly & Company, any security holder of Eli Lilly & Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (2), (3), (4), (5), (6), (7), (8), (9), and (10) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $314.85 to $315.84, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $315.85 to $316.84, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $316.85 to $317.84, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $317.85 to $318.845, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $318.85 to $319.845, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $319.85 to $320.83, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $320.865 to $321.82, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $321.905 to $322.815, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $323.165 to $324.06, inclusive. /s/Diane M. Stenson, Vice President & Treasurer, on behalf of Lilly Endowment Inc. 2022-05-31